Lantern Pharma Inc. Common Stock (LTRN) Stock Price

LTRNStock
$0.67−84.53%52W
Market Cap$9.98M
P/E—
PEG Ratio—
Div yield—
Beta2.44

LTRN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-81.22%
Price vs S&P 500 (4W)-54.11%
VGM Score13.74

LTRN Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.38-$0.28+26.63%(+$0.10)
Q1 2026-$0.36-$0.30+16.67%(+$0.06)
Q4 2025-$0.46-$0.36+21.74%(+$0.10)
Q3 2025-$0.47-$0.39+17.02%(+$0.08)
Q2 2025-$0.48-$0.40+17.53%(+$0.08)

LTRN Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.13

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
LTRNLantern Pharma Inc. Common Stock
——F————$0.67
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Lantern Pharma Inc. Common Stock

Lantern Pharma uses artificial intelligence to accelerate oncology drug discovery and development. The company's proprietary RADR platform applies machine learning to oncology-focused data, reducing drug development costs and timelines. Its growing pipeline of precision cancer therapies is powered by AI-driven insights and partnerships with leading scientific experts.